Literature DB >> 10447131

Beneficial effects of dietary supplementation in a disorder with defective synthesis of cholesterol. A case report of a girl with Smith-Lemli-Opitz syndrome, polyneuropathy and precocious puberty.

L Starck1, I Björkhem, E M Ritzén, B Y Nilsson, U von Döbeln.   

Abstract

In 1993 the Smith-Lemli-Opitz (SLO) syndrome, known as a malformation syndrome characterized by certain stigma, turned out to be a metabolic disease with a defect in the last step of cholesterol biosynthesis. This led to the possibility of identifying affected individuals by biochemical methods and of increasing understanding of pathogenic mechanisms. Hopes of influencing the effects of the metabolic defect by dietary supplementation were raised and reports with some benefits of treatment have been published. This is a report of a 12-y-old girl with the SLO syndrome in an apparently progressive form. In addition to typical signs and well-known symptoms she has a verified polyneuropathy and precocious puberty. She has been treated with cholesterol and bile acids for 3 y, during which time the progressive course has been arrested. A notable effect has been the improvement of her polyneuropathy, verified by measurement of nerve conduction velocities. Possible mechanisms involved in the pathogenesis of her precocious puberty are discussed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10447131     DOI: 10.1080/08035259950169008

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  7 in total

1.  Diagnosis of Smith-Lemli-Opitz syndrome from stored filter paper blood specimens.

Authors:  L Starck; A Lövgren
Journal:  Arch Dis Child       Date:  2000-06       Impact factor: 3.791

Review 2.  Molecular regulators of nerve conduction - Lessons from inherited neuropathies and rodent genetic models.

Authors:  Jun Li
Journal:  Exp Neurol       Date:  2015-03-17       Impact factor: 5.330

Review 3.  Lipid metabolism in myelinating glial cells: lessons from human inherited disorders and mouse models.

Authors:  Roman Chrast; Gesine Saher; Klaus-Armin Nave; Mark H G Verheijen
Journal:  J Lipid Res       Date:  2010-11-09       Impact factor: 5.922

4.  Clinical utility gene card for: Smith-Lemli-Opitz Syndrome [SLOS].

Authors:  Martina Witsch-Baumgartner; Hilary Sawyer; Dorothea Haas
Journal:  Eur J Hum Genet       Date:  2013-01-16       Impact factor: 4.246

5.  Effects of cholesterol and simvastatin treatment in patients with Smith-Lemli-Opitz syndrome (SLOS).

Authors:  D Haas; S F Garbade; C Vohwinkel; N Muschol; F K Trefz; J M Penzien; J Zschocke; G F Hoffmann; P Burgard
Journal:  J Inherit Metab Dis       Date:  2007-05-11       Impact factor: 4.982

6.  A placebo-controlled trial of simvastatin therapy in Smith-Lemli-Opitz syndrome.

Authors:  Christopher A Wassif; Lisa Kratz; Susan E Sparks; Courtney Wheeler; Simona Bianconi; Andrea Gropman; Karim A Calis; Richard I Kelley; Elaine Tierney; Forbes D Porter
Journal:  Genet Med       Date:  2016-08-11       Impact factor: 8.822

7.  Dietary cholesterol supplementation and inhibitory factor 1 serum levels in two dizygotic Smith-Lemli-Opitz syndrome twins: a case report.

Authors:  Maurizio Delvecchio; Biagio Rapone; Simonetta Simonetti; Simona Fecarotta; Graziana De Carlo; Elvira Favoino; Maria Teresa Loverro; Anna Maria Isdraele Romano; Federica Taurino; Edoardo Di Naro; Antonio Gnoni
Journal:  Ital J Pediatr       Date:  2020-10-28       Impact factor: 2.638

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.